A dual-hormone artificial pancreas (DAP) with a rapid delivery of insulin and pramlintide in a fixed ratio improves glycaemic control and reduces glucose variability in adults with type 1 diabetes (T1D) compared with first-generation artificial pancreas delivering insulin alone, according to a study presented at ADA 2018.
Combining the dual sodium glucose cotransporter (SGLT) 1 and 2 inhibitor sotagliflozin with optimized insulin therapy led to sustained reductions in HbA1c levels over 1 year in adults with type 1 diabetes (T1D), according to a study presented at ADA 2018.
Combined treatment with the GLP-1 receptor agonist exenatide and the SGLT-2 inhibitor dapagliflozin appeared to be effective up to 2 years in patients with type 2 diabetes (T2D), the phase III DURATION-8 extension trial has shown.
The sodium glucose co-transporter 2 (SGLT-2) inhibitor canagliflozin does not appear to increase the risk of below-knee lower extremity amputations over other SGLT2 inhibitors or non-SGLT2 inhibitor antihyperglycaemic agents in patients with type 2 diabetes (T2D), but may reduce the risk of hospitalization for heart failure (HHF), according to findings of the US-based OBSERVE-4D* study.
Intensified multipronged treatment in patients with type 2 diabetes (T2D) for 7.8 years is not associated with any significant increase in total costs or in costs per person-year when compared to conventional multipronged treatment over a follow-up of 21.2 years, according to the results of the Steno 2 Study presented at the 78th Scientific Sessions of the American Diabetes Association (ADA 2018).
The addition of the sodium-glucose cotransporter-2 inhibitor ertugliflozin to metformin improved glycaemic control, body weight, and blood pressure (BP) in patients with inadequately controlled type 2 diabetes (T2D), according to the results of the VERTIS MET* trial presented at ADA 2018.
Clinical and academic medicine, particularly in the field of diabetes, are not free of gender disparities, according to an all-female panel of industry leaders held at the recent 78th Scientific Sessions of the American Diabetes Association (ADA 2018).
Acculturation appears to predispose Asian Indian immigrants in the US to type 2 diabetes and cardiovascular disease, with the adoption of American lifestyle behaviours having an impact on glycated haemoglobin and high-density lipoprotein cholesterol levels, according to a study.
Adding the selective SGLT2* inhibitor dapagliflozin to insulin therapy improves HbA1c levels in patients with inadequately controlled type 1 diabetes (T1D), according to the DEPICT-2** study presented at ADA 2018.
Dr Michael Lim, a senior consultant at the Paediatric Pulmonary and Sleep Division, National University Hospital, Singapore, speaks to Roshini Claire Anthony on the rare disease that is cystic fibrosis.
Empagliflozin treatment in patients with type 2 diabetes mellitus exerts beneficial effects on cardiovascular (CV) risk factors, including blood pressure and uric acid, according to a systematic review and meta-analysis.
A 10 or 20 mg/kg daily dose of cannabidiol could almost halve the risk of seizures in children with Dravet syndrome, according to the phase III GWPCARE2* study presented at the American Academy of Neurology annual meeting (AAN 2019).